Loading...
High residual platelet reactivity after acute myocardial infarction (AMI) is associated with ischemic events, including stent thrombosis, prompting the development of new clopidogrel dosing regimens and more-potent antiplatelet agents. In this Korean study, 90 AMI patients underwent coronary stenting and were then randomized to receive aspirin plus either standard clopidogrel therapy (75 mg/day), high-maintenance-dose clopidogrel therapy (150 mg/day), or triple therapy consisting of standard clopidogrel therapy plus the phosphodiesterase III inhibitor cilostazol (100 mg twice daily).
The level of platelet inhibition before hospital discharge was similar in all three treatment groups. However, at 30-day follow-up, maximal platelet aggregation…